The big pharma company's top drug is losing ground, but its dividend keeps rising.Shares of Big Pharma company AbbVie (ABBV 0.33%) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on the stock from $180 to $214 per share on Friday, July 19.Bullishness for AbbVie might seem foolhardy to the casual observer. The company's lead drug, Humira, finally lost patent-protected exclusivity in the U.S. market last year, a ...

Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.Dividend growth stocks typically outperform most other asset classes over five- to 10-year periods. I've selected 10 companies with strong dividend growth records that could amplify your portfolio returns over the long term.These blue-chip companies have navigated various headwinds while continuing to increase their payouts at a blistering rate. Let's examine why these top dividend growers might be worth bu ...

Portfolio Overview - The portfolio consists of 6 stocks and 1 ETF, designed for a 10-year buy-and-hold strategy with a focus on income and dividend growth [1][2] - The portfolio aims to provide an average income of 4%, dividend growth of 6%, and a total return of 10% or better [2] - The portfolio is defensive in nature, with only 14% allocation to technology compared to 35% in the S&P500 [4] Individual Stock Analysis Enterprise Products Partners LP (EPD) - EPD is a midstream energy company with a 7.2% yield and a 25-year history of dividend increases [6][8] - The company has a solid balance sheet, A- credit rating, and $4 billion in liquidity [10] - EPD generated $1.9 billion in distributable cash flow in Q1 2024, covering dividends by 1.7x [9] Main Street Capital (MAIN) - MAIN is a BDC with a 5.75% forward yield and a history of special distributions, bringing total yield to 7.5%-8% [11][12] - The company has $7 billion in investment capital and a diversified portfolio of 190 investments [11] - MAIN's distributable net investment income exceeded dividends by 54% in Q1 2024 [12] Microsoft (MSFT) - MSFT is a leader in AI, with a 21% growth in its Azure platform and Intelligent Cloud in Q3 2023 [15] - The company has a 0.66% yield and is trading near its 52-week high [3][15] Mid-America Apartments Communities (MAA) - MAA is a REIT with a 4.3% yield and a strong balance sheet with an A- credit rating [16] - The company owns 100,000+ residential apartments in the sun-belt region of the US [16] PepsiCo (PEP) - PEP is a Dividend King with a 50+ year history of dividend increases and a 3.3% yield [19][20] - The company reported a 0.8% increase in revenue to $22.5 billion in Q2 2024 [21] Canadian National Railways (CNI) - CNI has a 2.01% yield and a 27-year history of dividend increases [3][24] - The company moved 300 million tons of cargo in 2023 and has access to seven major ports [22] Schwab U.S. Dividend Equity ETF (SCHD) - SCHD is a diversified ETF with a 3.85% forward yield and a 0.06% expense ratio [25] - The fund has a 10.8% annualized return from July 2014 to June 2024 [26]

Supatman/iStock via Getty Images I recently exited our position in AbbVie (NYSE:ABBV) from my family's income account. As communicated in this brief post, we set a limit sell order for our ABBV shares at $175 on June 25, 2024. The order was triggered yesterday. We started accumulating our shares about three years ago and have been publishing our bullish thesis periodically since we first started writing for Seeking Alpha in 2021 (see the chart below, and you can see our first coverage on the stock her ...

tifonimages/iStock via Getty Images Investment Overview AbbVie Inc. (NYSE:ABBV), the North Chicago, Illinois-based Pharma giant formed via a spin out of Abbott Laboratories' (ABT) pharmaceuticals division in 2012, will announce its Q2 2024 earnings next Thursday, 25th July. It's a new era for the company in more ways than one. Firstly, it will be the first time AbbVie's long-term CEO Rick Gonzalez will not be presiding over the earnings call with analysts. The CEO officially retired from his position on Jul ...

While active acquisition is perhaps the most common methodology of gaining wealth, it’s not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea. So, you need to find a way to have your money make money, which is where high-yield dividend stocks come into play.When participating in the equities space, it’s generally a good idea to have exposure to passive-income-providing enterp ...

You can buy these solid stocks at some attractive discounts right now.Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to score some great deals in the market.Three stocks that bargain hunters may want to consider buying today are AbbVie (ABBV 0.70%), Verizon Communications (VZ 1.62%), and PayP ...

At this writing, current inflation rate is 3% over the past 12 months. That’s the reading as of the end of June. So, in searching for high-yield dividend stocks beating inflation, I need to identify those with dividend yields above 3%.Fortunately, there are plenty of options in that range for investors. As always, it’s best to search within what is considered the healthy range of 2% to 6%. That’s a good rule of thumb, although there are exceptions to the rule.Consumers are fed up with inflation, although th ...

U.S. News & World Report recently said the New York Fed’s Recession Probability model hints that within the next 12 months, we stand a 55.8% chance of a recession. One can never be too safe though. So, some proactive investors are currently looking toward recession proof stocks to shield their portfolios in 2024.Investors are worried that the same AI stocks that have driven markets higher in 2024 may be a bubble. Inflation is cooling, standing at 3% as of July 11. The Federal Reserve may be cutting interest ...

AbbVie Inc. (ABBV) announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for its JAK inhibitor, Rinvoq (upadacitinib), for a new indication.The company is seeking approval for once-daily Rinvoq (15 mg) for treating adult patients with giant cell arteritis (GCA), an autoimmune disease-causing inflammation of the large arteries.The regulatory filings for GCA were based on data from the phase III SELECT-GCA study, which evaluated the safety ...